Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Apr 14;11(14):2174-8.
doi: 10.3748/wjg.v11.i14.2174.

Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C

Affiliations

Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C

Yutaka Yamanaka et al. World J Gastroenterol. .

Abstract

Aim: To analyze the risk factors of hepatocellular carcinoma (HCC) recurrence after radiofrequency ablation (RFA) treatment with HCV-associated hepatitis.

Methods: Twenty-six patients with HCV-associated HCC who were followed-up for more than 12 mo were selected for this study. Risk factors for distant intrahepatic recurrences of HCC were evaluated for patients in whom complete coagulation was achieved without recurrence in the same subsegment as the primary nodule. Twelve clinical and tumoral factors were examined: Age, gender, nodule diameter, number of primary HCC nodule, Child-Pugh classification, serum platelet, serum albumin, serum AST, post RFA AST, serum ALT, post RFA ALT, post RFA treatment.

Results: Distant recurrences of HCC in remnant liver after RFA were observed in 14 cases and in the number of primary HCC nodules (P = 0.047), and the serum platelets (P = 0.030), the clear difference came out by the recurrence group and the non-recurrence group. The cumulative recurrence rates after 1 and 2 years were 30.8% and 86.8%, respectively for primary multinodular HCC, and 15.4% and 29.5% respectively, for primary uninodular HCC. In addition the 1-year recurrence rates for patients with serum albumin more than 3.4 g/dL and less than 3.4 g/dL were 23.1% for both, but the 2-years recurrence rates were 89.0% and 23.1%, respectively. The number of primary HCC nodules (relative risk, 6.970; P = 0.016) were found to be a statistically significant predictor for poor distant intrahepatic recurrence by univariate analysis.

Conclusion: Patients who have multiple HCC nodules, low serum platelets and low serum albumin accompanied by HCV infection, should be carefully followed because of the high incidence of new HCC lesions in the remnant liver, even if coagulation RFA is complete.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distant intrahepatic recurrence curves by subsets of tumor count before RFA. The recurrence rates after 1 and 2 years were 30.8% and 86.8%, respectively, for primary multinodular HCC and 15.4% and 29.5% respectively, for primary uninodular HCC. Primary multinodular HCC was significantly (P = 0.0136) associated with a higher distant intrahepatic recurrence rate compared with primary uninodular HCC.
Figure 2
Figure 2
Distant intrahepatic recurrence curves by subsets of serum albumin before RFA. The one-year recurrence rate for patients with serum albumin of more than 3.4 g/L and less than 3.4 g/L were both 23.1%, but the two-year recurrence rates were 89.0% and 23.1%, respectively.

Similar articles

Cited by

References

    1. Fontana RJ, Hamidullah H, Nghiem H, Greenson JK, Hussain H, Marrero J, Rudich S, McClure LA, Arenas J. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl. 2002;8:1165–1174. - PubMed
    1. Francica G, Marone G. Ultrasound-guided percutaneous treatment of hepatocellular carcinoma by radiofrequency hyperthermia with a 'cooled-tip needle'. A preliminary clinical experience. Eur J Ultrasound. 1999;9:145–153. - PubMed
    1. Yamakado K, Nakatsuka A, Ohmori S, Shiraki K, Nakano T, Ikoma J, Adachi Y, Takeda K. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol. 2002;13:1225–1232. - PubMed
    1. Yamakado K, Nakatsuka A, Akeboshi M, Shiraki K, Nakano T, Takeda K. Combination therapy with radiofrequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma: Short-term recurrences and survival. Oncol Rep. 2004;11:105–109. - PubMed
    1. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. Cancer. 2001;91:1342–1348. - PubMed